BioAtla, Inc.

We are a clinical-stage biopharmaceutical company focused on developing a new class of highly specific and selective antibody-based treatments for solid tumor cancers. Our conditionally active biologics, or CABs, utilize our proprietary discoveries in tumor biology to target known tumor antigens that have previously been challenging to address. These CAB therapeutic candidates exploit the characteristic acidic pH of the tumor microenvironment, which differs from healthy tissue. We design our antibodies to selectively bind to targets on cancer cells under acidic pH conditions, but not on targets in normal tissues. Our strategy aims to achieve the necessary targeting and potency for cancer cell destruction while eliminating or significantly reducing on-target, off-tumor toxicity, a common challenge with existing cancer therapies. The enhanced selectivity of our CAB technology is intended to improve the benefit-risk ratio for patients and allows for desired drug levels as monotherapy or in multi-targeted or combination therapies. The combination of reversible binding with the selective, precision capability of our CAB technology enables both increased antibody potency and reduced toxicity. Our proprietary CAB technology has the potential to transform antibody-based cancer therapy. Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to improve patients' quality of life. Our CAB technology's broad applicability allows us to develop various product candidate modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), T cell-engaging bispecific antibodies, and chimeric antigen receptor T cells (CAR-T cells).